Gilead Sciences
GILD
1,561 hedge funds and large institutions have $78.8B invested in Gilead Sciences in 2016 Q3 according to their latest regulatory filings, with 101 funds opening new positions, 648 increasing their positions, 676 reducing their positions, and 120 closing their positions.
4% less repeat investments, than reductions
Existing positions increased: 648 | Existing positions reduced: 676
2% less funds holding
Funds holding: 1,599 → 1,561 (-38)
3.23% less ownership
Funds ownership: 78.88% → 75.65% (-3.2%)
9% less capital invested
Capital invested by funds: $86.8B → $78.8B (-$8.01B)
16% less call options, than puts
Call options by funds: $2.11B | Put options by funds: $2.5B
16% less first-time investments, than exits
New positions opened: 101 | Existing positions closed: 120
18% less funds holding in top 10
Funds holding in top 10: 130 → 106 (-24)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$384M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$379M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
+$273M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$225M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$201M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.98B |
| 2 |
JP Morgan Chase
New York
|
-$560M |
| 3 |
EIP
Epoch Investment Partners
New York
|
-$362M |
| 4 |
GE
General Electric
Evendale,
Ohio
|
-$321M |
| 5 |
Goldman Sachs
New York
|
-$290M |
GILD Hedge Fund Activity: Q3 2016 in Review
1,561 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2016, worth a combined $78.8B — down 9.2% from $86.8B a quarter earlier.
Sellers outnumbered buyers: 120 funds closed out of GILD and 101 opened new positions — a net loss of 19 holders — while 676 trimmed existing stakes and 648 added.
The largest buyer was State Street, adding an estimated $384M. The largest seller was Fidelity Investments, cutting an estimated $1.98B.
- 1,561 institutional investors held Gilead Sciences (GILD) as of Q3 2016, down from 1,599 in Q2 2016.
- Funds reported $78.8B of Gilead Sciences stock for Q3 2016, down 9.2% quarter-over-quarter.
- 101 funds opened new Gilead Sciences positions in Q3 2016 and 120 closed out, a net change of -19 holders.
- The largest Gilead Sciences buyer in Q3 2016 was State Street, an estimated $384M added.
- The largest Gilead Sciences seller in Q3 2016 was Fidelity Investments, an estimated $1.98B sold.
Based on aggregated 13F filings for Q3 2016.